Clinical Trials: From the Editor
1-20 of 38 Next
177Lutetium-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer; Randomized Controlled Phase 3 Trial Data is Pending and Novel Combinations are Being Tested
Is Chemoimmunotherapy Prime Time for First-Line Metastatic Urothelial Carcinoma?
Results from a first-line chemoimmunotherapy trial in patients with metastatic urothelial carcinoma were recently presented at the 2019 European Society of Medical Oncology (ESMO) Congress.1 These early results from the IMvigor 130 trial provide the first hints that novel combination therapy offers benefit for patients with locally advanced or metastatic urothelial carcinoma. This trial randomized patients to atezolizumab plus platinum/gemcitabine (Arm A) vs. atezolizumab monotherapy (Arm B) vs. placebo plus platinum/gemcitabine (Arm C).
The CARD Trial Creates a New Standard… For Certain Patients
At the European Society of Medical Oncology (ESMO) Congress 2019, the randomized phase 3 CARD trial was presented, with a simultaneous publication in the New England Journal of Medicine.1 This trial randomized 255 men with metastatic castration-resistant prostate cancer in a 1:1 fashion, who previously received docetaxel and an Androgen-Signaling-targeted Inhibitor (ASI), either abiraterone or enzalutamide, to cabazitaxel 25 mg/m2 plus prednisone and granulocyte colony-stimulating factor or the other ASI.
What Works for Breast Cancer Should Work for Prostate Cancer, Right?
Is HER2 Still a Worthwhile Therapeutic Target for Urothelial Bladder Cancer?
Polycomb Complex Enhancer of Zeste 2 (EZH2), a Regulator of Lineage Reprogramming and a New Drug Target
Heating Things Up in a Volatile Marriage…Bispecific Antibody Therapy in Prostate Cancer
Enzalutamide and Apalutamide Now Offer Survival Benefit for Patients with Metastatic Castration-Sensitive Prostate Cancer, But How Do Things Change Now and What Should We Be Doing Next?
Androgen Receptor Mutations in Prostate Cancer, a Worthwhile Therapeutic Target?
The Next Step in Bladder Cancer Immune-Oncology Therapy? Combination Therapy!
Fluciclovine (Axumin®) PET/CT Imaging in Prostate Cancer: More Uses than Just for Recurrent Disease?
PARP with PD-1/PD-L1 inhibition: Is There Any Magic to the Combination in a Molecularly Unselected Patient Population?
Is Testosterone Such a Bad Thing for Prostate Cancer? Rationale for Using Supraphysiologic Testosterone to Treat Castration-Resistant Prostate Cancer
Clinical Trial Updates of Single-Agent PARP Inhibitor Use in Homologous Recombination Deficient Prostate Cancer Populations
Are More Indications for Local Therapy of Prostate Cancer on the Horizon?
Sipuleucel-T… Beyond the IMPACT Trial
Prostate-Specific Membrane Antigen (PSMA)-Targeted Radioligand Therapies are Finally Arriving
Why Aren’t There More Systemic Therapy Trials for Patients with Muscle-invasive Urothelial Carcinoma of the Bladder?
Just recently, we discussed neoadjuvant systemic therapy for cisplatin-ineligible patients with muscle-invasive urothelial carcinoma of the bladder.1 For those patients “unfit” for cisplatin with at least one of the following criteria: creatinine clearance <60 ml/min, grade ≥2 hearing loss, grade ≥2 neuropathy, ECOG performance status 2, and/or New York Heart Association Class III heart failure,2 there are no good options other than cystectomy alone. Yet, we know the outcomes are not ideal for these patients with cystectomy alone. Finding systemic therapies that may improve outcomes for these patients is clearly an unmet need in the field.
Adjuvant Therapy for Renal Cell Carcinoma?
How Can I Keep My Bladder, Doc? The BCG Refractory Non-Muscle Invasive Bladder Cancer Question
1-20 of 38 Next